Abstract
Study Objective: To determine whether a new Sonoclot-based, aprotinin-insensitive activated clotting time (aiACT) assay yields stable results over a broad range of aprotinin concentrations. Design: Prospective trial conducted on in vitro blood samples. Setting: Tertiary-care teaching medical center. Participants: 19 healthy adult volunteers. Interventions: Whole blood samples were collected from volunteers. Heparin (2 U/mL) and escalating concentrations of aprotinin of 160 to 500 kallikrein inhibitory units (KIU)/mL were added in vitro. Measurements and Main Results: Celite ACT, kaolin ACT, and aiACT assays were completed. The aiACT showed stable activated clotting time (ACT) results on heparinized, noncitrated blood with added aprotinin (P = nonsignificant). In contrast, celite ACT and kaolin ACT were greatly prolonged when aprotinin was added to heparinized, noncitrated, and citrated blood (P < 0.05). The aiACT had consistent results at all aprotinin concentrations (P = nonsignificant). Conclusions: Aprotinin (160, 320, and 500 KIU/mL) significantly prolongs the ACT value with celite and kaolin activators but not with the aprotinin-insensitive activator.
Original language | English (US) |
---|---|
Pages (from-to) | 424-428 |
Number of pages | 5 |
Journal | Journal of Clinical Anesthesia |
Volume | 19 |
Issue number | 6 |
DOIs | |
State | Published - Sep 2007 |
Externally published | Yes |
Keywords
- Activated clotting time
- Anticoagulation
- Aprotinin
- Aprotinin-insensitive ACT
- Cardiopulmonary bypass
- Sonoclot analysis
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine